JP3126539B2 - Skin roughness improver - Google Patents
Skin roughness improverInfo
- Publication number
- JP3126539B2 JP3126539B2 JP05082690A JP8269093A JP3126539B2 JP 3126539 B2 JP3126539 B2 JP 3126539B2 JP 05082690 A JP05082690 A JP 05082690A JP 8269093 A JP8269093 A JP 8269093A JP 3126539 B2 JP3126539 B2 JP 3126539B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- butyl
- methoxydibenzoylmethane
- tert
- skin roughness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Description
【0001】[0001]
【産業上の利用分野】本発明は、優れた肌荒れ改善効果
を有し、皮膚外用剤に好適な肌荒れ改善剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention provides an excellent effect of improving rough skin.
And a skin roughness improving agent suitable for an external preparation for skin .
【0002】[0002]
【従来の技術および発明が解決しようとする課題】皮膚
外用剤には種々の薬効剤が配合され、肌荒れ防止効果は
薬効の一つであり、肌荒れ防止、肌荒れ改善効果のある
薬効剤が待望されている。従来、核酸類が肌荒れ改善に
用いられてきたが、その効果はいまだ充分ではなく効果
を期待するには、及ばなかった。本発明者らは核酸類の
肌荒れ防止、肌荒れ改善効果を高める方法はないものか
と鋭意研究した結果、4−tert−ブチル−4’−メトキ
シジベンゾイルメタンとリボ核酸、デオキシリボ核酸及
びそれらの塩の群から選ばれる一種とを配合することに
よって、この目的が達成できることを見出して本発明を
完成するに至った。2. Description of the Related Art Various agents are incorporated into skin external preparations, and the effect of preventing rough skin is one of the medicinal effects. ing. Conventionally, nucleic acids have been used to improve skin roughness, but their effects have not been sufficient yet and have not been sufficient to expect the effects. The inventors of the present invention have conducted intensive studies on a method for preventing roughening of nucleic acids and improving the roughening effect of the nucleic acids. As a result, 4-tert-butyl-4′-methoxydibenzoylmethane and ribonucleic acid, deoxyribonucleic acid and their salts It has been found that this object can be achieved by blending with one selected from the group, and the present invention has been completed.
【0003】[0003]
【課題を解決するための手段】即ち、本発明は、4−te
rt−ブチル−4’−メトキシジベンゾイルメタンとリボ
核酸、デオキシリボ核酸及びそれらの塩の群から選ばれ
る一種とを配合し、リボ核酸、デオキシリボ核酸及びそ
れらの塩の配合量が0.005〜0.5重量%で、かつ
リボ核酸、デオキシリボ核酸及びそれらの塩に対する4
−tert−ブチル−4’−メトキシジベンゾイルメタンの
配合量が1〜100倍であり、ビタミンE及び/又はそ
の誘導体が配合されていない肌荒れ改善剤を提供するも
のである。That is, the present invention provides a 4-te
rt-butyl-4'-methoxydibenzoylmethane is mixed with ribonucleic acid, deoxyribonucleic acid and one selected from the group of salts thereof, and the amount of ribonucleic acid, deoxyribonucleic acid and salts thereof is 0.005 to 0 0.5% by weight and 4% by weight of ribonucleic acid, deoxyribonucleic acid and their salts.
Amount of -tert- butyl-4'-methoxydibenzoylmethane is Ri 1-100 Baidea, vitamin E and / or its
The present invention provides a skin roughness improving agent not containing a derivative of
【0004】以下、本発明の構成について詳述する。本
発明に使用される4−tert−ブチル−4’−メトキシジ
ベンゾイルメタンは特開昭55−66535号公報によ
って公知である。Hereinafter, the configuration of the present invention will be described in detail. 4-tert-butyl-4'-methoxydibenzoylmethane used in the present invention is known from JP-A-55-66535.
【0005】本発明に用いられる核酸類は公知の物質で
あって、それらの塩類としてはリボ核酸またはデオキシ
リボ核酸と、無機塩基または有機塩基とからなる塩が適
用され、好ましくはリボ核酸またはデオキシリボ核酸の
ナトリウム塩、カリウム塩、特に好ましくはリジン塩、
アルギニン塩が適用される。[0005] The nucleic acids used in the present invention are known substances, and as the salts thereof, salts composed of ribonucleic acid or deoxyribonucleic acid and inorganic bases or organic bases are applied. Preferably, ribonucleic acid or deoxyribonucleic acid is used. Sodium salt, potassium salt, particularly preferably lysine salt,
Arginine salt is applied.
【0006】本発明におけるリボ核酸、デオキシリボ核
酸及びそれらの塩の配合量が0.005〜0.5重量%
で、さらに好ましくは、0.05〜0.5重量%であ
る。0.005重量%未満では、その効果は4−tert−
ブチル−4’−メトキシジベンゾイルメタンをともに配
合しても期待できない。また、0.5重量%までとした
のは、肌荒れ改善効果のためにはこの程度の量で充分な
る効果を発揮でき、この量を超えても効果に差異がない
ためである。肌荒れ改善剤への4−tert−ブチル−4’
−メトキシジベンゾイルメタンの配合量は、核酸類に対
して重量で1〜100倍である。両物質の相乗効果はこ
の範囲内で最もよく発揮される。In the present invention, the content of ribonucleic acid, deoxyribonucleic acid and their salts is 0.005 to 0.5% by weight.
More preferably, the content is 0.05 to 0.5% by weight. At less than 0.005% by weight, the effect is 4-tert-
It cannot be expected to mix butyl-4'-methoxydibenzoylmethane. Moreover, what it was up to 0.5% by weight, for skin roughness improvement effect can be exhibited sufficiently Naru effect in an amount of this degree, because there is no difference even beyond this amount effect. 4-tert-butyl-4 'for roughening agent
The amount of methoxydibenzoylmethane is 1 to 100 times the weight of nucleic acids. The synergistic effect of both substances is best exhibited within this range.
【0007】本発明の肌荒れ改善剤は前記の必須成分に
加えて必要に応じ、本発明の効果を損なわない範囲で、
化粧品、医薬品等に用いられる各種成分、すなわち、水
性成分、粉末成分、油分、界面活性剤、保湿剤、増粘
剤、防腐剤、酸化防止剤、色材、紫外線吸収剤、薬剤等
を配合することができる。[0007] In addition to the above essential components, the skin roughness improving agent of the present invention may be used, if necessary, as long as the effects of the present invention are not impaired.
Contains various components used in cosmetics, pharmaceuticals, etc., ie, aqueous components, powder components, oils, surfactants, humectants, thickeners, preservatives, antioxidants, coloring materials, ultraviolet absorbers, drugs, etc. be able to.
【0008】また、本発明の剤型は任意であり、例えば
化粧水系の可溶化系、乳液、クリーム等の乳化あるいは
軟膏、分散粉末製品などの剤型をとることができる。[0008] The dosage form of the present invention is optional. For example, the dosage form may be a solubilizing system of a lotion, an emulsion such as an emulsion or cream, or an ointment or a dispersion powder product.
【0009】[0009]
【実施例】つぎに、試験例および実施例によって本発明
を説明する。 試験例1 下記の処方のクリームにおいて4−tert−ブチル−4’
−メトキシジベンゾイルメタンを0重量%、5重量%、
核酸類を0重量%、0.5重量%と変化させたクリーム
で人体パネルで肌荒れ改善効果の試験を行った。すなわ
ち、女性健康人(顔面)の皮膚表面形態をミリスチン樹
脂によるレプリカ法を用いて肌のレプリカを取り、顕微
鏡(17倍)にて観察する。皮紋の状態及び角層の剥離
状態から表1に示す肌荒れ評価1,2と判断された者
(肌荒れパネル)30名を用い、顔面左右半々に塗布し
戸外で1時間経過させる。1週間後再びレプリカを取
り、肌の状態を観察し、表1の判断基準に従って評価し
た。Next, the present invention will be described with reference to Test Examples and Examples. Test Example 1 4-tert-butyl-4 'in a cream having the following formulation
0% by weight of methoxydibenzoylmethane, 5% by weight,
The nucleic acids 0 wt%, was tested for rough skin improving effect in the human body panel cream was changed to 0.5 wt%. That is, the skin surface morphology of a healthy female person (face) is replicated using a myristine resin replica method and observed with a microscope (17 ×). Using 30 people (rough skin panels) judged to have skin roughness evaluations 1 and 2 shown in Table 1 based on the state of the skin print and the peeling state of the stratum corneum, the composition is applied to the left and right half of the face and left for 1 hour outdoors. One week later, a replica was taken again, the condition of the skin was observed, and the skin was evaluated according to the criteria shown in Table 1.
【0010】[0010]
【表1】 [Table 1]
【0011】処方 A セタノール 0.5% ワセリン 2.0 スクワラン 7.0 自己乳化型モノステアリン酸グリセリン 2.5 POEソルビタンステアリン酸エステル(20E.O.) 1.5 4−tert−ブチル−4’−メトキシジベンゾイルメタン 5.0 ホホバ油 5.0 B プロピレングリコール 5.0 グリセリン 5.0 ビーガム 5.0 水酸化カリウム 0.3 核酸類 0〜0.5 水 残余 製法 A(油相)とB(水相)をそれぞれ70度に加熱し、完
全溶解する。AをBに加えて、乳化機で乳化する。乳化
機を熱交換機を用いて冷却して、クリームを得た。この
クリームを上記評価方法に従って評価を行った結果を表
2に示す。Formulation A Cetanol 0.5% Vaseline 2.0 Squalane 7.0 Self-emulsifying glyceryl monostearate 2.5 POE Sorbitan stearate (20EO) 1.5 4-tert-butyl-4 ' -Methoxydibenzoylmethane 5.0 Jojoba oil 5.0 B Propylene glycol 5.0 Glycerin 5.0 Vegum 5.0 Potassium hydroxide 0.3 Nucleic acids 0-0.5 Water Residual process A (oil phase) and B (Aqueous phase) is heated to 70 ° C. and completely dissolved. Add A to B and emulsify with an emulsifier. The emulsifier was cooled using a heat exchanger to obtain a cream. Table 2 shows the results of evaluation of this cream according to the above evaluation method.
【0012】[0012]
【表2】 [Table 2]
【0013】この結果より核酸類の一種又は二種以上と
4−tert−ブチル−4’−メトキシジベンゾイルメタン
を配合した皮膚外用剤を使用した顔面部位を他の皮膚外
用剤を使用した顔面部位と比較し、顕著な肌荒れ改善効
果が認められた。 From these results, it was found that a facial part using a skin external preparation containing one or more nucleic acids and 4-tert-butyl-4′-methoxydibenzoylmethane was replaced with a facial part using another skin external preparation. Remarkably improved skin roughness compared to
Fruit was observed.
【0014】実施例1 クリーム 処方 A ステアリン酸 10.0% ステアリルアルコール 4.0 ステアリン酸ブチル 8.0 ステアリン酸モノグリセリンエステル 2.0 4−tert−ブチル−4’−メトキシジベンゾイルメタン 2.0 香料 0.4 防腐剤 適量 B プロピレングリコール 10.0 グリセリン 4.0 水酸化カリウム 0.4 リボ核酸 0.5 エデト酸三ナトリウム 0.05 精製水 残余 A(油相)とB(水相)をそれぞれ70度に加熱し、完
全溶解して、通常の方法によってクリームを得た。これ
を試料として上記評価試験を行ったところ、良好な結果
を得た。Example 1 Cream Formulation A Stearic acid 10.0% Stearyl alcohol 4.0 Butyl stearate 8.0 Stearic acid monoglycerin ester 2.0 4-tert-butyl-4'-methoxydibenzoylmethane 2.0 Perfume 0.4 Preservative appropriate amount B Propylene glycol 10.0 Glycerin 4.0 Potassium hydroxide 0.4 Ribonucleic acid 0.5 Trisodium edetate 0.05 Purified water Residue A (oil phase) and B (aqueous phase) Each was heated to 70 ° C. and completely dissolved to obtain a cream by a usual method. When the above evaluation test was performed using this as a sample, good results were obtained.
【0015】実施例2 口紅 処方 パラフィン 10.0% マイクロクリスタリンワックス 8.0 ワセリン 15.0 流動パラフィン 残余 2−オクチルドデカノール 19.5 アルギン酸ナトリウム 1.0 硫酸カルシウム 1.0 赤色104号の(1)アルミニウムレーキ 4.0 酸化チタン 1.0 4−tert−ブチル−4’−メトキシジベンゾイルメタン 0.5 デオキシリボ核酸 0.2 通常の方法によって口紅を得た。これを試料として上記
評価試験を行ったところ、良好な結果を得た。Example 2 Lipstick Formula Paraffin 10.0% Microcrystalline Wax 8.0 Vaseline 15.0 Liquid Paraffin Residue 2-octyldodecanol 19.5 Sodium Alginate 1.0 Calcium Sulfate 1.0 Red No. 104 (1) ) Aluminum lake 4.0 Titanium oxide 1.0 4-tert-Butyl-4'-methoxydibenzoylmethane 0.5 Deoxyribonucleic acid 0.2 Lipstick was obtained by the usual method. When the above evaluation test was performed using this as a sample, good results were obtained.
【0016】[0016]
【発明の効果】以上記載のとおり本発明の肌荒れ改善剤
は、核酸類の持つ肌荒れ改善効果を著しく増加させるこ
とが明らかである。As described above, it is clear that the skin roughness improving agent of the present invention significantly increases the skin roughness improving effect of nucleic acids.
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) A61K 7/48 A61K 7/00 ──────────────────────────────────────────────────続 き Continued on the front page (58) Field surveyed (Int.Cl. 7 , DB name) A61K 7/48 A61K 7/00
Claims (1)
ンゾイルメタンとリボ核酸、デオキシリボ核酸及びそれ
らの塩の群から選ばれる一種とを配合し、リボ核酸、デ
オキシリボ核酸及びそれらの塩の配合量が0.005〜
0.5重量%で、かつリボ核酸、デオキシリボ核酸及び
それらの塩に対する4−tert−ブチル−4’−メトキシ
ジベンゾイルメタンの配合量が1〜100倍であり、ビ
タミンE及び/又はその誘導体が配合されていない肌荒
れ改善剤。1. A mixture of 4-tert-butyl-4'-methoxydibenzoylmethane with one selected from the group consisting of ribonucleic acid, deoxyribonucleic acid and salts thereof, and a mixture of ribonucleic acid, deoxyribonucleic acid and salts thereof. The amount is 0.005
0.5 wt%, and ribonucleic acid, the amount of 4-tert-butyl-4'-methoxydibenzoylmethane against deoxyribonucleic acid and salts thereof Ri 1-100 Baidea, bi-
Skin rough without Tamine E and / or its derivatives
Remedy .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP05082690A JP3126539B2 (en) | 1993-03-16 | 1993-03-16 | Skin roughness improver |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP05082690A JP3126539B2 (en) | 1993-03-16 | 1993-03-16 | Skin roughness improver |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06271451A JPH06271451A (en) | 1994-09-27 |
JP3126539B2 true JP3126539B2 (en) | 2001-01-22 |
Family
ID=13781418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP05082690A Expired - Lifetime JP3126539B2 (en) | 1993-03-16 | 1993-03-16 | Skin roughness improver |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3126539B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6979644B2 (en) * | 2017-08-30 | 2021-12-15 | 株式会社 ナチュラル | UV shielding cosmetic composition |
-
1993
- 1993-03-16 JP JP05082690A patent/JP3126539B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH06271451A (en) | 1994-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3483988B2 (en) | Skin preparation | |
EP0616799A1 (en) | Cosmetic delivery system for salicylic acid and process for preparation of same | |
JPH08325136A (en) | Alpha-hydroxycarboxylic acid containing petroleum jelly | |
JP5069965B2 (en) | Topical skin preparation | |
JP4518367B2 (en) | Pore reducing agent | |
JP2003342195A (en) | Inhibitor for parakeratosis, pore reducing agent and external preparation for skin | |
JPH01275511A (en) | External drug for skin | |
JPH064529B2 (en) | External skin preparation | |
JP2549119B2 (en) | Topical | |
JP4828077B2 (en) | Topical skin preparation | |
JP3126539B2 (en) | Skin roughness improver | |
JPH10279419A (en) | Preparation for external use for skin | |
JP2004307414A (en) | W/o/w emulsion skin care preparation for external use and method for producing the same | |
JPH07215839A (en) | Skin external agent | |
JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
JP3119491B2 (en) | Topical melanin production inhibitor | |
JPH10203921A (en) | Skin preparation for external use | |
JPH06128137A (en) | Cosmetic | |
JPH11193212A (en) | Skin preparation for external use for keeping and enhancing skin ph buffering ability | |
JP2000344651A (en) | Skin lotion | |
JP2000256168A (en) | Skin lotion | |
JPH10273413A (en) | Skin preparation for external use | |
JPH115725A (en) | Preparation for external use for skin | |
JPH10203920A (en) | Skin preparation for external use | |
JPH06263625A (en) | External agent for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121102 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131102 Year of fee payment: 13 |